Biotech intelligence for BD, strategy, and research teams
What companies do, not what they say. Trial changes, SEC filings, and market data from primary sources.
Pharma Strategic Signals
Business development signals detected from biotech SEC 8-K filings, updated daily.
Signal Volume by Week
|
Filed
|
Company |
|---|---|
|
"...expenses while the Company explores a range of strategic alternatives, the Board of Directors of the Company approved on January 21, 2026, a restructuring and workforce reduction plan (the "Plan") which is expected to result in a significant reduction of the Company's..."
|
|
|
Jan 30, 2026
Show excerpt"...expenses while the Company explores a range of strategic alternatives, the Board of Directors of the Company approved on January 21, 2026, a restructuring and workforce reduction plan (the "Plan") which is expected to result in a significant reduction of the Company's..."
|
|
|
"...release announcing that it plans to explore strategic alternatives. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein. Item 9.01 Financial Statements and Exhibits...."
|
|
|
Jan 21, 2026
Show excerpt"...release announcing that it plans to explore strategic alternatives. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein. Item 9.01 Financial Statements and Exhibits...."
|
|
|
"...services to support the Company's pursuit of strategic alternatives. In such consulting roles, Dr. Palasis will continue to serve as the Company's principal executive officer and Mr. Cavalier will continue to serve as the Company's principal financial officer...."
|
|
|
Jan 12, 2026
Show excerpt"...services to support the Company's pursuit of strategic alternatives. In such consulting roles, Dr. Palasis will continue to serve as the Company's principal executive officer and Mr. Cavalier will continue to serve as the Company's principal financial officer...."
|
|
|
"...prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's diabetes, oncology and/or other clinical development programs including..."
|
|
|
Jan 7, 2026
Show excerpt"...prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's diabetes, oncology and/or other clinical development programs including..."
|
|
|
"...prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's diabetes, oncology and/or other clinical development programs including..."
|
|
|
Jan 6, 2026
Show excerpt"...prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's diabetes, oncology and/or other clinical development programs including..."
|
|
|
"...with respect to identifying and consummating a strategic alternative transaction. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform..."
|
|
|
Dec 16, 2025
Show excerpt"...with respect to identifying and consummating a strategic alternative transaction. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform..."
|
|
|
"...Simultaneously, the Company is reviewing other strategic alternatives. Forward-Looking Statements This Current Report contains express or implied "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S...."
|
|
|
Dec 8, 2025
Show excerpt"...Simultaneously, the Company is reviewing other strategic alternatives. Forward-Looking Statements This Current Report contains express or implied "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S...."
|
|
Understanding Pharma Strategic Signals
This page monitors SEC 8-K filings from biotech and pharmaceutical companies to surface events relevant to business development and corporate strategy teams.
Strategic Reviews
Companies announcing they are "exploring strategic alternatives" - typically indicating openness to acquisition, merger, or asset sale. These are explicit intent signals.
Licensing Deals
Material definitive agreements involving licensing, collaboration, co-development, or partnership arrangements between companies.
Capital Formation
Public offerings, private placements, ATM programs, and other financing events that affect a company's cash position and runway.
Data source: SEC EDGAR. Filings typically available within 4 hours of submission. Signals are captured only when explicitly disclosed in filings.
Get Signals Filtered for Your Coverage
We build focused data tools for BD, strategy, and research teams. Tell us what you track and we'll send you signals filtered by therapeutic area, deal type, or company size.